HRP20170687T1 - Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora - Google Patents
Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora Download PDFInfo
- Publication number
- HRP20170687T1 HRP20170687T1 HRP20170687TT HRP20170687T HRP20170687T1 HR P20170687 T1 HRP20170687 T1 HR P20170687T1 HR P20170687T T HRP20170687T T HR P20170687TT HR P20170687 T HRP20170687 T HR P20170687T HR P20170687 T1 HRP20170687 T1 HR P20170687T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell depleting
- antibody
- use according
- depleting agent
- cell
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims 16
- 230000000779 depleting effect Effects 0.000 title claims 16
- 239000003795 chemical substances by application Substances 0.000 title claims 11
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims 4
- 239000012634 fragment Substances 0.000 title claims 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Agens za iscrpljivanje B-stanica za uporabu u liječenju sindroma kroničnog umora i mijalgičkog encefalomijelitisa gdje je agens koji iscrpljuje B-stanice deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment protutijela.
2. Deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment za uporabu u skladu s patentnim zahtjevom 1, koje je monoklonsko protutijelo ili njegov CD20-vezujući fragment protutijela.
3. Agens za iscrpljivanje B-stanica za uporabu u skladu s patentnim zahtjevom 1, koji je humanizirano anti CD20 protutijelo ili njegov CD20-vezujući fragment protutijela.
4. Agens za iscrpljivanje B-stanica za uporabu u skladu s patentnim zahtjevom 1, koji je antigen vezujući fragment odabran iz grupe koja se sastoji od F(ab’)2, F(ab’), Fab, Fv i sFv.
5. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva koji je odabran između humaniziranih protutijela rituksimaba, ofatumumaba, okrelizumaba, GA101 ili veltuzumaba.
6. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je količina za B-stanice deplecijskog anti CD20 protutijela u rasponu od 10 mg do 5000 mg po doziranju.
7. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je deplecijsko anti CD20 protutijelo za B-stanice ili njegov CD20-vezujući fragment protutijela za davanje subjektu u pojedinačnoj terapijski učinkovitoj dozi navedenog protutijela od 50 do 2000 mg/m2 ili višestrukim terapijski učinkovitim dozama navedenog anti CD20 protutijela ili anti CD20 vezujućeg fragmenta protutijela od 50 do 2000 mg/m2.
8. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7 primjenom jedne ili dviju infuzija navedenog deplecijskog agensa za B-stanice dva puta unutar dva tjedna.
9. Agens za iscrpljivanje B-stanica za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva karakteriziran primjenom kombinacije deplecijskog anti CD20 protutijela za B-stanice ili njegovog CD20-vezujućeg fragmenta protutijela istovremeno, zasebno ili u slijedu s metotreksatom subjektu koji pati od sindroma kroničnog umora ili mijalgičkog encefalomijelitisa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1855108P | 2008-01-02 | 2008-01-02 | |
| EP08000006A EP2077281A1 (en) | 2008-01-02 | 2008-01-02 | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| PCT/EP2009/000003 WO2009083602A1 (en) | 2008-01-02 | 2009-01-02 | B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP09700128.3A EP2235060B1 (en) | 2008-01-02 | 2009-01-02 | B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170687T1 true HRP20170687T1 (hr) | 2017-09-08 |
Family
ID=39402622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170687TT HRP20170687T1 (hr) | 2008-01-02 | 2017-05-08 | Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP2077281A1 (hr) |
| JP (1) | JP5722044B2 (hr) |
| KR (1) | KR101652530B1 (hr) |
| CN (1) | CN101910201B (hr) |
| AU (1) | AU2009203117B2 (hr) |
| BR (1) | BRPI0906172A2 (hr) |
| CA (1) | CA2706899C (hr) |
| CY (1) | CY1118918T1 (hr) |
| DK (1) | DK2235060T3 (hr) |
| ES (1) | ES2625728T3 (hr) |
| HR (1) | HRP20170687T1 (hr) |
| HU (1) | HUE034127T2 (hr) |
| IL (1) | IL206767A (hr) |
| LT (1) | LT2235060T (hr) |
| PL (1) | PL2235060T3 (hr) |
| PT (1) | PT2235060T (hr) |
| RU (1) | RU2519229C2 (hr) |
| SI (1) | SI2235060T1 (hr) |
| WO (1) | WO2009083602A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011203879A1 (en) * | 2010-01-11 | 2012-08-02 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
| EP2805730A1 (en) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Nitric oxide donor for the treatment of chronic fatigue syndrome |
| CN105813637A (zh) * | 2013-11-01 | 2016-07-27 | 卑尔根技术转移公司 | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 |
| WO2016102530A1 (en) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| EP4021457A1 (en) | 2019-08-30 | 2022-07-06 | Vestlandets Innovasjonsselskap AS | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0970207B1 (en) | 1997-02-10 | 2009-04-01 | Genentech, Inc. | Heregulin variants |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| AU8296098A (en) | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| NZ528199A (en) | 1998-08-11 | 2005-06-24 | Idec Pharma Corp | Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| WO2000027433A1 (en) | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
| PT1616572E (pt) | 1998-11-09 | 2010-11-11 | Biogen Idec Inc | Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6383276B1 (en) | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| HUP0201009A2 (en) | 1999-05-07 | 2002-07-29 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US7074403B1 (en) | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
| DE19930748C2 (de) | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| CN1373672A (zh) | 1999-07-12 | 2002-10-09 | 杰南技术公司 | 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答 |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| JP2003513012A (ja) | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
| US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| RU2305561C2 (ru) | 1999-11-08 | 2007-09-10 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US20030185796A1 (en) | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| AU2001247737A1 (en) | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
| CN1981868A (zh) | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| JP2003531178A (ja) | 2000-04-25 | 2003-10-21 | アイデック ファーマスーティカルズ コーポレイション | 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与 |
| EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| SI1296714T1 (sl) | 2000-06-22 | 2010-01-29 | S For Entpr University Of Iowa | Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka |
| AU6461201A (en) | 2000-07-12 | 2002-01-21 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| KR20040023565A (ko) | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
| AU2002213357A1 (en) | 2000-10-20 | 2002-05-06 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
| IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
| US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| WO2002078766A2 (en) | 2001-04-02 | 2002-10-10 | Genentech, Inc. | Combination therapy |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
| EP1404366A4 (en) | 2001-06-14 | 2006-06-07 | Intermune Inc | COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| EP1438583B1 (en) | 2001-09-20 | 2009-09-16 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| JP2005538034A (ja) | 2001-12-07 | 2005-12-15 | カイロン コーポレイション | 非ホジキンリンパ腫の治療方法 |
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20030180292A1 (en) | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| US20030219818A1 (en) | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| DK3284753T3 (da) | 2002-10-17 | 2021-07-05 | Genmab As | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose |
| CA2542886A1 (en) * | 2003-11-05 | 2005-05-19 | Neelima M. Bhat | Enhanced b cell cytotoxicity of cdim binding antibody |
| CA2563432A1 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting b cell depletion |
| EP1919505A2 (en) * | 2005-07-25 | 2008-05-14 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
| DE102005035611C5 (de) | 2005-07-29 | 2014-05-15 | Diehl Aerospace Gmbh | Busarchitektur sowie Verfahren zum Datenaustausch |
| US20090202531A1 (en) * | 2005-11-01 | 2009-08-13 | Novartis Ag | Uses of anti-cd40 antibodies |
| CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
-
2008
- 2008-01-02 EP EP08000006A patent/EP2077281A1/en not_active Withdrawn
-
2009
- 2009-01-02 CA CA2706899A patent/CA2706899C/en not_active Expired - Fee Related
- 2009-01-02 HU HUE09700128A patent/HUE034127T2/en unknown
- 2009-01-02 WO PCT/EP2009/000003 patent/WO2009083602A1/en active Application Filing
- 2009-01-02 RU RU2010132178/15A patent/RU2519229C2/ru active
- 2009-01-02 LT LTEP09700128.3T patent/LT2235060T/lt unknown
- 2009-01-02 DK DK09700128.3T patent/DK2235060T3/en active
- 2009-01-02 ES ES09700128.3T patent/ES2625728T3/es active Active
- 2009-01-02 KR KR1020107014813A patent/KR101652530B1/ko active IP Right Grant
- 2009-01-02 CN CN200980101646.6A patent/CN101910201B/zh not_active Expired - Fee Related
- 2009-01-02 BR BRPI0906172-0A patent/BRPI0906172A2/pt not_active Application Discontinuation
- 2009-01-02 SI SI200931662T patent/SI2235060T1/sl unknown
- 2009-01-02 PT PT97001283T patent/PT2235060T/pt unknown
- 2009-01-02 EP EP09700128.3A patent/EP2235060B1/en active Active
- 2009-01-02 AU AU2009203117A patent/AU2009203117B2/en not_active Ceased
- 2009-01-02 JP JP2010541057A patent/JP5722044B2/ja not_active Expired - Fee Related
- 2009-01-02 PL PL09700128T patent/PL2235060T3/pl unknown
-
2010
- 2010-07-01 IL IL206767A patent/IL206767A/en active IP Right Grant
-
2017
- 2017-05-08 HR HRP20170687TT patent/HRP20170687T1/hr unknown
- 2017-05-22 CY CY20171100535T patent/CY1118918T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2077281A1 (en) | 2009-07-08 |
| LT2235060T (lt) | 2017-07-25 |
| PL2235060T3 (pl) | 2017-10-31 |
| BRPI0906172A2 (pt) | 2015-06-30 |
| AU2009203117A1 (en) | 2009-07-09 |
| JP5722044B2 (ja) | 2015-05-20 |
| WO2009083602A1 (en) | 2009-07-09 |
| SI2235060T1 (sl) | 2017-09-29 |
| PT2235060T (pt) | 2017-05-31 |
| RU2010132178A (ru) | 2012-02-10 |
| EP2235060A1 (en) | 2010-10-06 |
| CA2706899A1 (en) | 2009-07-09 |
| CY1118918T1 (el) | 2018-01-10 |
| CA2706899C (en) | 2017-02-28 |
| HUE034127T2 (en) | 2018-01-29 |
| ES2625728T3 (es) | 2017-07-20 |
| JP2011508754A (ja) | 2011-03-17 |
| KR101652530B1 (ko) | 2016-08-30 |
| RU2519229C2 (ru) | 2014-06-10 |
| DK2235060T3 (en) | 2017-06-06 |
| EP2235060B1 (en) | 2017-03-29 |
| CN101910201B (zh) | 2015-01-21 |
| CN101910201A (zh) | 2010-12-08 |
| KR20100116172A (ko) | 2010-10-29 |
| IL206767A0 (en) | 2010-12-30 |
| AU2009203117B2 (en) | 2014-10-23 |
| IL206767A (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170687T1 (hr) | Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora | |
| AU2012280267B2 (en) | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| JP2019513751A5 (hr) | ||
| Smith et al. | Painful rheumatoid arthritis | |
| JP2019518742A5 (hr) | ||
| JP2014533279A5 (hr) | ||
| JP2019506403A5 (hr) | ||
| NZ599278A (en) | Methods of reducing eosinophil levels | |
| JP2006522830A5 (hr) | ||
| JP2008540447A5 (hr) | ||
| JP2013512254A5 (hr) | ||
| JP2012046518A5 (hr) | ||
| JP2011504092A5 (hr) | ||
| JP2019517485A5 (hr) | ||
| ES2909722T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada | |
| US20200231666A1 (en) | Treatment paradigm | |
| JP2022137089A (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| JP2017529324A5 (hr) | ||
| JP2019512472A5 (hr) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| JP2013543869A5 (hr) | ||
| MX2021013248A (es) | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. | |
| WO2016003789A1 (en) | Combination therapy | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 |